Annual sales fell from KRW 38.1 billion in 2022 to KRW 9.76 billion in 2023, a 74.4% decline, and then to KRW 7.14 billion in 2024, down 26.9% and the smallest year in the 2022 to 2025 window. Sales recovered to KRW 9.4 billion in 2025, up 31.8%, but that is only a little above a quarter of the 2022 level.
The decline followed a peak of KRW 85.3 billion in 2020, a pattern that overlaps with falling demand for COVID-19 diagnostic reagents and instruments.
Operating income of KRW 14.7 billion in 2022 turned into an operating loss of KRW 7.09 billion in 2023, followed by an operating loss of KRW 9.16 billion in 2024 and KRW 8.64 billion in 2025, which makes three straight loss years. The operating margin improved from -128.4% in 2024 to -91.9% in 2025.
The net loss attributable to controlling shareholders reached KRW 11.6 billion in 2025, larger than the operating loss, which suggests non-operating items pulled earnings lower; the detailed items should be checked in the full annual report.
The debt-to-equity ratio rose from 20.9% in 2022 to 38.2% in 2025, with year-end total liabilities of KRW 25.9 billion and total equity of KRW 67.9 billion. Equity attributable to controlling shareholders of KRW 68.4 billion exceeds total equity, which means non-controlling interests are negative.
Operating cash flow went from KRW 13.6 billion in 2022 to -KRW 1.14 billion in 2023, -KRW 1.43 billion in 2024 and -KRW 7.01 billion in 2025, a widening outflow.
Quarterly sales rose from KRW 2.07 billion in Q3 2025 to KRW 3.09 billion in Q2 2026, then fell 17.5% quarter on quarter to KRW 2.55 billion in Q3 2026, still up 23.3% year on year. Operating loss narrowed from KRW 2.44 billion in Q3 2025 to KRW 1.97 billion in Q3 2026.
Net income attributable to controlling shareholders, however, was KRW 597 million in Q1 2026 and KRW 775 million in Q2, before a KRW 4.64 billion loss in Q3.
According to the company, the first-quarter profit reflected non-operating items such as foreign exchange gains and equity valuation gains at an investee, while package supply through a distribution partnership drove sales growth.
The combined net loss attributable to controlling shareholders over the latest four quarters is KRW 8.38 billion.